Cumulative Incidence of Venous Thromboembolism in Patients With Uterine Cancer

Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we identified women 65 years of age and older diagnosed with uterine cancer between 2008 and 2017 to evaluate the cumulative incidence of venous thromboembolism (VTE). Patients were followed from 6 months before to up to 10 years after diagnosis. A total of 683 patients with prevalent VTE (within 6 months before cancer diagnosis) were excluded. Among the remaining 25,204 patients with a median age of 72 years, 4,907 (19.5%) had VTE events during the follow-up period. The 10-year cumulative incidence of VTE increased with stage at diagnosis: 23.1% (95% CI 22.1-24.1%) for localized, 38.9% (95% CI 36.8-40.9%) for regional, and 56.5% (95% 51.0-61.7%) for distant disease. Our findings indicate a substantial and persistent thrombotic burden, particularly for patients with advanced-stage uterine cancer.